ARTICLE | Product Development
Will Altimmune’s pemvidutide be good enough to attract a partner? And will Pfizer go shopping after latest danuglipron data?
By Selina Koch, Executive Editor, and Gunjan Ohri, Data Content Analyst
December 2, 2023 1:18 AM UTC
Neither of Friday’s Phase II obesity readouts, one from Altimmune and one from Pfizer, pointed to best-in-class potential. However, with efficacy similar to Wegovy, Altimmune could be positioned to partner. Pfizer, by contrast, has paused its twice-daily danuglipron program, which could send the pharma shopping for a new therapy.
After opening Friday up 82%, shares of Altimmune Inc. (NASDAQ:ALT) finished the day up 13%, giving the company a market cap of about $192 million, as investors digested results from the Phase II MOMENTUM trial of pemvidutide. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650807/what-a-pair-of-phase-ii-obesity-results-could-mean-for-altimmune-pfizer